{
    "clinical_study": {
        "@rank": "157965", 
        "arm_group": {
            "arm_group_label": "Pregabalin", 
            "description": "Subjects who are treated with pregabalin"
        }, 
        "brief_summary": {
            "textblock": "To collect the efficacy and safety information of Pregabalin on Fibromyalgia patients\n      related to their appropriate use in daily practice."
        }, 
        "brief_title": "Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan)", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pain Associated With Fibromyalgia", 
        "condition_browse": {
            "mesh_term": [
                "Fibromyalgia", 
                "Myofascial Pain Syndromes"
            ]
        }, 
        "detailed_description": {
            "textblock": "All the patients whom an investigator prescribes the first pregabalin should be registered\n      consecutively until the number of subjects reaches target number in order to extract\n      patients enrolled into the investigation at random."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of Fibromyalgia\n\n          -  Pregabalin naive patient\n\n        Exclusion Criteria:\n\n          -  Clinical diagnosis of neuropathic pain"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Primary care clinic and hospital for Fibromyalgia"
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01773993", 
            "org_study_id": "A0081282"
        }, 
        "intervention": {
            "arm_group_label": "Pregabalin", 
            "description": "The usual adult dosage for oral use begins at 150 mg/day of pregabalin twice daily, and should be gradually increased to 300 mg/day over 1 week or more and then maintained at 300-450 mg/day as needed. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 450 mg, and should be orally administered twice daily.", 
            "intervention_name": "Pregabalin", 
            "intervention_type": "Drug", 
            "other_name": "Lyrica\u00ae Capsules 25 mg, Lyrica\u00ae Capsules 75 mg, Lyrica\u00ae Capsules 150 mg"
        }, 
        "intervention_browse": {
            "mesh_term": "Pregabalin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Lyrica", 
            "pregabalin", 
            "Good post marketing practice", 
            "Post Marketing Surveillance", 
            "Regulatory Post Marketing Commitment Plan", 
            "Fibromyalgia"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081282&StudyName=Special%20Investigation%20of%20Pregabalin%20for%20Fibromyalgia%20%28Regulatory%20Post%20Marketing%20Commitment%20Plan%29"
        }, 
        "number_of_groups": "1", 
        "official_title": "Special Investigation of Pregabalin (Lyrica) for Fibromyalgia", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The CGI-C scale measures a physician's global impression of a participant's clinical condition at final visit in terms of change relative to the start of treatment (CGI-C). At final visit, the participants CGI-C will be categorized into a three point scale as: improvement: CGI response of very much improved, much improved or minimally improved; no change: CGI response of no change; worsening: CGI response of very much worse, much worse or minimally worse", 
            "measure": "Number of Participants with Change from Baseline in Clinical Global Impression of Clinical Condition (CGI-C) at Month X", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01773993"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}